Loading
A phase 1 trial of MOMA-341 run by MOMA Therapeutics, now recruiting.
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors is a phase 1 interventional study registered as NCT06974110 by MOMA Therapeutics, with 132 participants planned, started 2025-07-16. Conditions recorded: Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer, Colorectal Cancer, Gastric Cancer and dMMR Cancer. Interventions recorded: MOMA-341, Irinotecan and Immunotherapy.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Endometrial cancer, Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Shares Endometrial cancer, Metastatic cancer (cancer that has spread), Colorectal cancer and the tag pipeline.
Shares MOMA Therapeutics, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Gastric & gastro-oesophageal junction cancer, Colorectal cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/